FSD Pharma Partners with iNGENu CRO for Lucid-MS Clinical Safety and Pharmacokinetics Study in Adults

FSD Pharma, a biopharmaceutical firm listed on NASDAQ and CSE, has announced the initiation of a Phase 1 clinical trial for a novel compound, Lucid-21-302, intended to treat multiple sclerosis (MS). The study, a collaboration with iNGENu CRO Pty Ltd, will assess the safety and pharmacokinetics of the drug in healthy adults through a randomized, double-blind, placebo-controlled, and multiple ascending dose design.

The compound, Lucid-21-302, is a patented entity that has demonstrated neuroprotective properties in preclinical trials, specifically by preventing demyelination, a process that leads to MS and other neurodegenerative conditions. The drug has shown promising results in an earlier Phase 1 study, where it was found to be safe and well-tolerated in a dosage range of 50-300 mg.

Zeeshan Saeed, CEO of FSD Pharma, expressed optimism about the partnership with iNGENu and the potential of Lucid-21-302 in advancing therapeutic solutions for MS. Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at FSD Pharma, highlighted the company's eagerness to efficiently complete the trial, buoyed by the robust data from the initial study.

FSD Pharma is committed to developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company's lead compound, Lucid-MS, formerly known as Lucid-21-302, is at the forefront of their research efforts. FSD Pharma has also entered into a licensing agreement with Celly Nutrition Corp. for a proprietary blend of ingredients aimed at alleviating the aftereffects of alcohol consumption.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!